Carolyn F. Deacon

Carolyn F. Deacon

Associate Professor


  1. 2001
  2. Published

    Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. / Meier, J.J.; Huking, K.; Holst, J.J.; Deacon, C.F.; Schmiegel, W.H.; Nauck, M.A.

    In: Diabetes, No. 50, 2001, p. 2497-2504.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 2000
  4. Published

    Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. / Deacon, C.F.; Nauck, M.A.; Meier, J.; Hücking, K.; Holst, J.J.

    In: Journal of Clinical Endocrinology and Metabolism, No. 85, 2000, p. 3575-3581.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    In vivo and in vitro degradation of glucagon-like peptide-2 in humans. / Hartmann, Bolette; Harr, M.B.; Jeppesen, P.B.; Wojdemann, M.; Deacon, C.F.; Mortensen, P.B.; Holst, J.J.

    In: Journal of Clinical Endocrinology and Metabolism, No. 85, 2000, p. 2884-2888.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. 1999
  7. Published

    Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. / Hansen, L; Deacon, C F; Orskov, C; Holst, J J.

    In: Molecular Endocrinology, Vol. 140, No. 11, 11.1999, p. 5356-63.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    Glucagon-like peptide-1 : a basis for new approaches to the management of diabetes. / Deacon, C F; Holst, Jens Juul; Carr, R D.

    In: Drugs of Today, Vol. 35, No. 3, 03.1999, p. 159-70.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. Published

    Glucagon-like peptide-1(7-36)amide is transformed to glucagon-like peptide-1 (9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the intestinal L-cells. / Hansen, L.; Deacon, C.F.; Ørskov, C.; Holst, J.J.

    In: Endokrinologiya, No. 140, 1999, p. 5356-5363.

    Research output: Contribution to journalJournal articleResearchpeer-review

  10. Published

    Glucagon-like peptide-1: A basis for new approaches to the management of Diabetes. / Deacon, C.F.; Holst, J.J.; Carr, R.D.

    In: Drugs of Today, No. 35, 1999, p. 159-170.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. 1998
  12. Published

    Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. / Deacon, C.F.; Hughes, T.E.; Holst, J.J.

    In: Diabetes, No. 47, 1998, p. 764-769.

    Research output: Contribution to journalJournal articleResearchpeer-review

  13. Published

    Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. / Deacon, C.F.; Knudsen, L.B.; Madsen, K.; Wiberg, F.C.; Jacobsen, O.; Holst, J.J.

    In: Diabetologia, No. 41, 1998, p. 271-278.

    Research output: Contribution to journalJournal articleResearchpeer-review

  14. Published

    Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. / Holst, J.J.; Deacon, C.F.

    In: Diabetes, No. 47, 1998, p. 1663-1670.

    Research output: Contribution to journalJournal articleResearchpeer-review

  15. Published

    On the treatment of diabetes mellitus with glucagon-like peptide-1. / Holst, J.J.; Deacon, C.F.; Toft-Nielsen, M.; Bjerre-Knudsen, L.

    In: Annals of the New York Academy of Sciences, No. 865, 1998, p. 336-343.

    Research output: Contribution to journalJournal articleResearchpeer-review

  16. 1997
  17. Published

    Posttranslational processing of proglucagon and postsecretory fate of proglucagon products. / Holst, Jens Juul; Ørskov, C.; Hartmann, Bolette; Deacon, C.F.

    The Insulinotropic Gut Hormone Glucagon-like Peptide-1.. Basel : Karger, 1997. p. 24-48.

    Research output: Chapter in Book/Report/Conference proceedingBook chapterResearch

  18. 1996
  19. Published

    Plasma TNF-x is associated with insulin mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. / Haugaard, S.B.; Andersen, O.; Pedersen, S.B.; Dela, Flemming; Deacon, C.F.

    In: Metabolism - Clinical and Experimental, No. 55(2), 1996, p. 175-182.

    Research output: Contribution to journalJournal articleResearchpeer-review

  20. 1995
  21. Published

    Both subcutaneously and intravenously administered glucagon-like peptide-1 are rapidly degraded from the amino terminus in type II diabetic patients and in healthy subjects. / Deacon, C.F.; Nauck, M.A.; Nielsen, M.T.; Pridal, L.; Holst, Jens Juul.

    In: Diabetes, No. 44, 1995, p. 1126-1131.

    Research output: Contribution to journalJournal articleResearchpeer-review

  22. Published

    Degradation of glucagon-like peptide-1 in vitro yields an N-terminally truncated peptide which is a major endogenous metabolite in vivo. / Deacon, C.F.; Johnsen, A.H.; Holst, Jens Juul.

    In: Journal of Clinical Endocrinology and Metabolism, No. 80, 1995, p. 952-957.

    Research output: Contribution to journalJournal articleResearchpeer-review

  23. Published

    Human colon produces fully processed glucagon-like peptide-1 (7-36 amide). / Deacon, C.F.; Johnsen, A.H.; Holst, Jens Juul.

    In: FEBS Letters, No. 372, 1995, p. 269-272.

    Research output: Contribution to journalJournal articleResearchpeer-review

Previous 1 2 3 Next

ID: 9220